ClinicalTrials.gg
CompletedNCT00938860SUSTAINUpdated May 22, 2015Results posted

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

A Phase 4 interventional study of cyclosporin (Neoral) and tacrolimus (Prograf) in Hepatitis C and Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 45 sites in 13 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-05-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Hepatitis C by Novartis — none open to participants now, none under way, none of them phase 3. Hepatitis C · Novartis.

Started
2009
the only one that year
Phase 4
2 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Hepatitis C by Novartis, this one is the only one that started in 2009, is one of 2 in phase 4, and was the 5th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 10 studies in Hepatitis C by Novartis is open now. The open studies under Hepatitis C, anywhere →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Hepatitis C by Novartis as a file.
02

Study summary

This study will assess the rates of Sustained Virological Response following anti-viral therapy with Peg-Interferon plus Ribavirin in patients that have been liver transplanted with recurrent Hepatitis C and treated with Neoral or tacrolimus.

03

Conditions studied

  • Hepatitis C
  • Liver Transplantation

Browse trials for

Keywords

  • Hepatitis C
  • liver transplantation
  • anti-viral therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Liver transplantation performed at least 6 months and up to 5 years prior randomization and due to cirrhosis, with or without pre-transplant hepatocellular carcinoma (HCC) within Milan or UCSF criteria
  • Immunosuppresive regimen based on tacrolimus b.i.d.- (twice or once daily) for at least 6 months prior randomization
  • Diagnosis of HCV genotypes 1 or 4 infection prior to transplantationconfirmed at screening
  • Indication of treatment with Peg-IFN and ribavirin due to histological evidence of chronic HCV infection defined as a fibrosis stage equal or greater than 1 using the Ishak-Knodell scoring system (IK ≥1) in a liver performed at screening or up to 4 months prior to randomization.

Exclusion criteria

Exclusion criteria:

  • Serum creatinine >150 μmol/L (1.6 7 mg/dL) or \< 50 ml/min (4-variable Modification of Diet in Renal Disease [MDRD formula])
  • Multi-organ transplant recipients
  • Recent episode of -treated acute rejection (AR) within 3 months prior to randomization, or >1 episode of steroid-treated AR in the last 6 months, or any number of steroid-resistant AR episodes in the last 6 months including evidence of chronic rejection or ductopenia
  • Evidence of conditions that could cause graft dysfunction other than infection
  • Patients with signs of decompensated liver disease, defined as presence of ascites, variceal bleeding, encephalopathy or deteriorated hepatic synthetic function (albumin \<3.5g/dL or, total direct >1.5mg/dL or, >1.5)
  • Co-infection with or (defined as HBsAg-positive) at screening
  • Use of mTOR inhibitors (everolimus or sirolimus) in the 6 months prior to screening
  • Antiviral treatment for HCV administered at any time after liver transplantation
  • Patients on daily doses of corticosteroids higher than 5 mg/day
  • Patients with fibrosing cholestatic hepatitis
  • Patients with current diagnosis of , including lymphoproliferative disorders
  • Patients with count \<70,000/mm3 or neutrophiles \<1,500/mm3
  • History of HCC outside Milan criteria based on radiology or UCSF criteria based on analysis of the explant
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Neoral

    Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges

    Drug: cyclosporin (Neoral)

  • Active comparator
    tacrolimus

    Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.

    Drug: tacrolimus (Prograf)

Interventions

  • Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges

  • Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.

06

What researchers measure

Primary outcomes

  1. Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus

    The achievement of SVR, defined as HCV RNA below limit of detection at the end of AV treatment, 24 weeks after end of AV treatment (W24 post). A dichotomous variable (SVR achieved: Yes/No) was computed. A patient was classified as non-responder (SVR not achieved) if HCV RNA was detectable at the completion of antiviral treatment, at W24post, or at any time between W24 and completion of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

    Time frame: Week 24

Secondary outcomes

  1. Number of Events of the Composite Endpoint of Biopsy Proven Acute Rejections (BPAR), Death or Graft Loss and of the Individual Components

    Efficacy failure (biopsy proven acute rejection (BPAR), graft loss, or death

    Time frame: Week 80

  2. Number of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline)

    Ishak-Knodell Score: 0=No fibrosis; 01=Fibrous expansion of some portal areas, with or without short fibrous septa; 02=Fibrous expansion of most portal areas, with or without short fibrous septa; 03=Fibrous expansion of most portal areas, with occasional portal to portal (P-P) bridging; 04=Fibrous expansion of portal areas, with marked bridging (portal to portal (P-P) as well as portal to central (P-C)); 05=Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis); 06=Cirrhosis, probable or definite, Participants showing an increase of Ishak Knodell fibrosis score by at least one level (increase of ≥1)

    Time frame: Week 80

  3. Number of Participants of Rapid Viral Response (RVR)

    RVR defined as non-detectable HCV RNA 4 weeks after initiation of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

    Time frame: Week 4

  4. Number of Participants of Early Viral Response (EVR)

    EVR defined as non-detectable HCV RNA or a ≥2 logs reduction of HCV RNA at 12 weeks after initiation of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

    Time frame: Week 12

  5. Number of Participants for the End of Treatment Response (ETR)

    ETR defined as non-detectable HCV RNA at the completion of AV treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

    Time frame: Week 80

  6. Number of Participants of True Non-responder Rate

    Defined as failure to achieve at least a 2 log reduction of Hepatitis C virus (HCV) RNA. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

    Time frame: Week 80

  7. Number of Participants for Relapse Rate

    Defined as reappearance of detectable Hepatitis C Virus (HCV) RNA at 24 weeks after completion of antiviral treatment when HCV RNA was undetectable at the end of treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

    Time frame: Week 24

  8. Number of Participants With Dose Reduction or Discontinuation of Antiviral (AV) Therapy Due to Poor Tolerability at Any Time During the Study for Any Reason

    Defined as number of patients with dose reduction or discontinuation of AV therapy due to poor tolerability

    Time frame: Week 80

07

Results

Posted May 26, 2014

Participant flow

Participant flow — Overall Study
MilestoneNeoralTacrolimus
Started5042
Efficacy population4041
Completed2525
Not completed2517
Withdrew: Adverse event21
Withdrew: Abnormal laboratory values22
Withdrew: Withdrawal by subject118
Withdrew: Lost to follow-up44
Withdrew: Administration problems20
Withdrew: Death11
Withdrew: Protocol violation31

Outcome measures

PrimaryNumber of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus

The achievement of SVR, defined as HCV RNA below limit of detection at the end of AV treatment, 24 weeks after end of AV treatment (W24 post). A dichotomous variable (SVR achieved: Yes/No) was computed. A patient was classified as non-responder (SVR not achieved) if HCV RNA was detectable at the completion of antiviral treatment, at W24post, or at any time between W24 and completion of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus
ParticipantsNeoralTacrolimus
Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus1210
SecondaryNumber of Events of the Composite Endpoint of Biopsy Proven Acute Rejections (BPAR), Death or Graft Loss and of the Individual Components

Efficacy failure (biopsy proven acute rejection (BPAR), graft loss, or death

Time frame:
Week 80
Reported as:
Number · Number of events
Number of Events of the Composite Endpoint of Biopsy Proven Acute Rejections (BPAR), Death or Graft Loss and of the Individual Components
Number of eventsNeoralTacrolimus
BPAR, graft loss, or death21
BPAR10
Graft loss or death11
Death11
SecondaryNumber of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline)

Ishak-Knodell Score: 0=No fibrosis; 01=Fibrous expansion of some portal areas, with or without short fibrous septa; 02=Fibrous expansion of most portal areas, with or without short fibrous septa; 03=Fibrous expansion of most portal areas, with occasional portal to portal (P-P) bridging; 04=Fibrous expansion of portal areas, with marked bridging (portal to portal (P-P) as well as portal to central (P-C)); 05=Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis); 06=Cirrhosis, probable or definite, Participants showing an increase of Ishak Knodell fibrosis score by at least one level (increase of ≥1)

Time frame:
Week 80
Reported as:
Number · Participants
Number of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline)
ParticipantsNeoralTacrolimus
Number of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline)35
SecondaryNumber of Participants of Rapid Viral Response (RVR)

RVR defined as non-detectable HCV RNA 4 weeks after initiation of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

Time frame:
Week 4
Reported as:
Number · Participants
Number of Participants of Rapid Viral Response (RVR)
ParticipantsNeoralTacrolimus
Number of Participants of Rapid Viral Response (RVR)45
SecondaryNumber of Participants of Early Viral Response (EVR)

EVR defined as non-detectable HCV RNA or a ≥2 logs reduction of HCV RNA at 12 weeks after initiation of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

Time frame:
Week 12
Reported as:
Number · Participants
Number of Participants of Early Viral Response (EVR)
ParticipantsNeoralTacrolimus
Number of Participants of Early Viral Response (EVR)2830
SecondaryNumber of Participants for the End of Treatment Response (ETR)

ETR defined as non-detectable HCV RNA at the completion of AV treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

Time frame:
Week 80
Reported as:
Number · Participants
Number of Participants for the End of Treatment Response (ETR)
ParticipantsNeoralTacrolimus
Number of Participants for the End of Treatment Response (ETR)2427
SecondaryNumber of Participants of True Non-responder Rate

Defined as failure to achieve at least a 2 log reduction of Hepatitis C virus (HCV) RNA. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

Time frame:
Week 80
Reported as:
Number · Participants
Number of Participants of True Non-responder Rate
ParticipantsNeoralTacrolimus
Number of Participants of True Non-responder Rate75
SecondaryNumber of Participants for Relapse Rate

Defined as reappearance of detectable Hepatitis C Virus (HCV) RNA at 24 weeks after completion of antiviral treatment when HCV RNA was undetectable at the end of treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants for Relapse Rate
ParticipantsNeoralTacrolimus
Number of Participants for Relapse Rate57
SecondaryNumber of Participants With Dose Reduction or Discontinuation of Antiviral (AV) Therapy Due to Poor Tolerability at Any Time During the Study for Any Reason

Defined as number of patients with dose reduction or discontinuation of AV therapy due to poor tolerability

Time frame:
Week 80
Reported as:
Number · Participants
Number of Participants With Dose Reduction or Discontinuation of Antiviral (AV) Therapy Due to Poor Tolerability at Any Time During the Study for Any Reason
ParticipantsNeoralTacrolimus
Neoral Antiviral treatment: Ribavirin250
Neoral Antiviral treatment: Peg-IFN100
Tacrolimus Antiviral treatment: Ribavirin023
Tacrolimus Antiviral treatment: Peg-IFN011

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tacrolimus—17/42 (40.5%)41/42 (97.6%)
Neoral—18/50 (36%)42/50 (84%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventTacrolimusNeoral
AnaemiaBlood and lymphatic system disorders5/426/50
PyrexiaGeneral disorders3/422/50
Urinary tract infectionInfections and infestations0/423/50
Abdominal pain upperGastrointestinal disorders2/420/50
DiarrhoeaGastrointestinal disorders2/420/50
CholestasisHepatobiliary disorders2/420/50
EncephalopathyNervous system disorders2/421/50
SyncopeNervous system disorders2/420/50
Abdominal painGastrointestinal disorders1/422/50
AstheniaGeneral disorders1/422/50
Most frequent other events
Showing 10 of 43
Most frequent other events
EventTacrolimusNeoral
AnaemiaBlood and lymphatic system disorders28/4227/50
NeutropeniaBlood and lymphatic system disorders14/426/50
FatigueGeneral disorders13/4212/50
DiarrhoeaGastrointestinal disorders11/429/50
NauseaGastrointestinal disorders11/426/50
AstheniaGeneral disorders10/427/50
LeukopeniaBlood and lymphatic system disorders9/4210/50
DizzinessNervous system disorders8/424/50
DyspnoeaRespiratory, thoracic and mediastinal disorders8/425/50
HypertensionVascular disorders4/429/50

Baseline characteristics

Intent-to-Treat (ITT) population: The ITT population consisted of all randomized patients.

Age, Continuous
Age, Continuous(Years)NeoralTacrolimusTotal
Mean54.2 ± 6.3055.0 ± 6.8454.6 ± 6.53
Sex: Female, Male
Sex: Female, Male(Participants)NeoralTacrolimusTotal
Female9817
Male413475
08

Study locations

45 sites
  • Novartis Investigative Site
    Phoenix, Arizona 85054, United States
  • Novartis Investigative Site
    Palo Alto, California 95128, United States
  • Novartis Investigative Site
    San Francisco, California 94143-2205, United States
  • Novartis Investigative Site
    Gainesville, Florida 32610, United States
  • Novartis Investigative Site
    Chapel Hill, North Carolina 27599-7211, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73112, United States
  • Novartis Investigative Site
    Houston, Texas 77030-2400, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Madison, Wisconsin 53792, United States
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Fortaleza, CE 60430-270, Brazil
  • Novartis Investigative Site
    São Paulo, SP 04023-900, Brazil
  • Novartis Investigative Site
    Edmonton, Alberta T6G 2B7, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Winnipeg, Manitoba R3E 0W3, Canada
  • Novartis Investigative Site
    London, Ontario N6A 4G5, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2C4, Canada
  • Novartis Investigative Site
    Bogotá, Cundinamarca 110111, Colombia
  • Novartis Investigative Site
    Bogotá, Colombia
  • Novartis Investigative Site
    Creteil, 94000, France
  • Novartis Investigative Site
    Lyon Cedex 04, 69317, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75012, France
  • Novartis Investigative Site
    Toulouse Cedex 4, 31054, France
  • Novartis Investigative Site
    Villejuif, 94800, France
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Seoul, Korea 110 744, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 120-752, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 135-710, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 137-701, Korea, Republic of
  • Novartis Investigative Site
    Moscow, 123182, Russian Federation
  • Novartis Investigative Site
    Moscow, 129010, Russian Federation
  • Novartis Investigative Site
    Oviedo, Asturias 33006, Spain
  • Novartis Investigative Site
    Valladolid, Castilla y Leon 47012, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Birmingham, B15 2TT, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2009
First posted
Jul 14, 2009
Start
Sep 2009
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
May 26, 2014
Last update
May 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00938860
Responsible party
Sponsor
First posted
Jul 14, 2009
Start date
Sep 2009
Primary completion
May 2013
Completion
May 2013
Results posted
May 26, 2014
Last update
May 22, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion